Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126080023 | 12608002 | 3 | F | 201607 | 20160912 | 20160729 | 20160915 | EXP | CN-JNJFOC-20160721229 | JANSSEN | 40.00 | YR | A | F | Y | 0.00000 | 20160915 | CN | CN | CN |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126080023 | 12608002 | 1 | PS | TOPAMAX | TOPIRAMATE | 1 | Unknown | FIRST WEEK-2 TAB, QD (IN EVENING); SECOND WEEK- 2 TAB, BID, THIRD WEEK-2 TAB-MORNING AND 3 TAB-EVE | Y | N | 140627635 | 20505 | 25 | MG | TABLETS |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 126080023 | 12608002 | 1 | Epilepsy |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 126080023 | 12608002 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 126080023 | 12608002 | Asthenia | |
| 126080023 | 12608002 | Drug ineffective | |
| 126080023 | 12608002 | Epilepsy | |
| 126080023 | 12608002 | Fear | |
| 126080023 | 12608002 | Hypoaesthesia | |
| 126080023 | 12608002 | Mental impairment | |
| 126080023 | 12608002 | Tic |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 126080023 | 12608002 | 1 | 20160724 | 0 |